SELLAS Life Sciences Group announced that it has streamlined its executive leadership to further focus on advancing the Company’s clinical programs while optimizing resource allocation. As part of this effort, Senior Vice President, Chief Commercial Officer, CCO, Robert Francomano and Executive Vice President, General Counsel and Corporate Secretary, Barbara Wood, will be departing the Company.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SLS:
- SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
- Largest borrow rate increases among liquid names
- SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference
- Sellas Life Sciences delivers oral presentation of SLS009 Phase 1 data
- Sellas Life Sciences to present SLS009 Phase 1 data ay 2024 ESH
